Noninvasive Assessment of IDH Mutational Status in World Health Organization Grade II and III Astrocytomas Using DWI and DSC-PWI Combined with Conventional MR Imaging

References

1. 1.↵
   2. Daumas-Duport C,
   3. Scheithauer B,
   4. O'Fallon J, et al

   . Grading of astrocytomas: a simple and reproducible method. Cancer 1988;62:2152–65 pmid:3179928

   CrossRefPubMedWeb of Science
2. 2.↵
   2. Fuller GN,
   3. Scheithauer BW

   . The 2007 Revised World Health Organization (WHO) Classification of Tumours of the Central Nervous System: newly codified entities. Brain Pathol 2007;17:304–07 doi:10.1111/j.1750-3639.2007.00084.x pmid:17598822

   CrossRefPubMedWeb of Science
3. 3.↵
   2. van den Bent MJ

   . Interobserver variation of the histopathological diagnosis in clinical trials on glioma: a clinician's perspective. Acta Neuropathol 2010;120:297–304 doi:10.1007/s00401-010-0725-7 pmid:20644945

   CrossRefPubMedWeb of Science
4. 4.↵
   2. Louis DN,
   3. Perry A,
   4. Reifenberger G, et al

   . The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathol 2016;131:803–20 doi:10.1007/s00401-016-1545-1 pmid:27157931

   CrossRefPubMed
5. 5.↵
   2. Parsons DW,
   3. Jones S,
   4. Zhang X, et al

   . An integrated genomic analysis of human glioblastoma multiforme. Science 2008;321:1807–12 doi:10.1126/science.1164382 pmid:18772396

   Abstract/FREE Full Text
6. 6.↵
   2. Hartmann C,
   3. Meyer J,
   4. Balss J, et al

   . Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas. Acta Neuropathol 2009;118:469–74 doi:10.1007/s00401-009-0561-9 pmid:19554337

   CrossRefPubMedWeb of Science
7. 7.↵
   2. Yan H,
   3. Parsons DW,
   4. Jin G, et al

   . IDH1 and IDH2 mutations in gliomas. N Engl J Med 2009;360:765–73 doi:10.1056/NEJMoa0808710 pmid:19228619

   CrossRefPubMedWeb of Science
8. 8.↵
   2. Balss J,
   3. Meyer J,
   4. Mueller W, et al

   . Analysis of the IDH1 codon 132 mutation in brain tumors. Acta Neuropathol 2008;116:597–602 doi:10.1007/s00401-008-0455-2 pmid:18985363

   CrossRefPubMedWeb of Science
9. 9.↵
   2. Watanabe T,
   3. Nobusawa S,
   4. Kleihues P, et al

   . IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas. Am J Pathol 2009;174:1149–53 doi:10.2353/ajpath.2009.080958 pmid:19246647

   CrossRefPubMedWeb of Science
10. 10.↵
    2. Olar A,
    3. Wani KM,
    4. Alfaro-Munoz KD, et al

    . IDH mutation status and role of WHO grade and mitotic index in overall survival in grade II–III diffuse gliomas. Acta Neuropathol 2015;129:585–96 doi:10.1007/s00401-015-1398-z pmid:25701198

    CrossRefPubMed
11. 11.↵
    2. Nikiforova MN,
    3. Hamilton RL

    . Molecular diagnostics of gliomas. Arch Pathol Lab Med 2011;135:558–68 doi:10.1043/2010-0649-RAIR pmid:21526954

    CrossRefPubMed
12. 12.↵
    2. Reuss DE,
    3. Mamatjan Y,
    4. Schrimpf D, et al

    . IDH mutant diffuse and anaplastic astrocytomas have similar age at presentation and little difference in survival: a grading problem for WHO. Acta Neuropathol 2015;129:867–73 doi:10.1007/s00401-015-1438-8 pmid:25962792

    CrossRefPubMed
13. 13.↵
    2. Sanson M,
    3. Marie Y,
    4. Paris S, et al

    . Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas. J Clin Oncol 2009;27:4150–54 doi:10.1200/JCO.2009.21.9832 pmid:19636000

    Abstract/FREE Full Text
14. 14.↵
    2. Bleeker FE,
    3. Atai NA,
    4. Lamba S, et al

    . The prognostic IDH1 (R132) mutation is associated with reduced NADP+-dependent IDH activity in glioblastoma. Acta Neuropathol 2010;119:487–94 doi:10.1007/s00401-010-0645-6 pmid:20127344

    CrossRefPubMedWeb of Science
15. 15.↵
    2. Krell D,
    3. Mulholland P,
    4. Frampton AE, et al

    . IDH mutations in tumorigenesis and their potential role as novel therapeutic targets. Future Oncol 2013;9:1923–35 doi:10.2217/fon.13.143 pmid:24295421

    CrossRefPubMed
16. 16.↵
    2. Rohle D,
    3. Popovici-Muller J,
    4. Palaskas N, et al

    . An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells. Science 2013;340:626–30 doi:10.1126/science.1236062 pmid:23558169

    Abstract/FREE Full Text
17. 17.↵
    2. Metellus P,
    3. Coulibaly B,
    4. Colin C, et al

    . Absence of IDH mutation identifies a novel radiologic and molecular subtype of WHO grade II gliomas with dismal prognosis. Acta Neuropathol 2010;120:719–29 doi:10.1007/s00401-010-0777-8 pmid:21080178

    CrossRefPubMedWeb of Science
18. 18.↵
    2. Kickingereder P,
    3. Sahm F,
    4. Radbruch A, et al

    . IDH mutation status is associated with a distinct hypoxia/angiogenesis transcriptome signature which is non-invasively predictable with rCBV imaging in human glioma. Sci Rep 2015;5:16238 doi:10.1038/srep16238 pmid:26538165

    CrossRefPubMed
19. 19.↵
    2. Schaefer PW,
    3. Grant PE,
    4. Gonzalez RG

    . Diffusion-weighted MR imaging of the brain. Radiology 2000;217:331–45 doi:10.1148/radiology.217.2.r00nv24331 pmid:11058626

    CrossRefPubMedWeb of Science
20. 20.↵
    2. Le Bihan D

    . Looking into the functional architecture of the brain with diffusion MRI. Nat Rev Neurosci 2003;4:469–80 doi:10.1038/nrn1119 pmid:12778119

    CrossRefPubMedWeb of Science
21. 21.↵
    2. Humphries PD,
    3. Sebire NJ,
    4. Siegel MJ, et al

    . Tumors in pediatric patients at diffusion-weighted MR imaging: apparent diffusion coefficient and tumor cellularity. Radiology 2007;245:848–54 doi:10.1148/radiol.2452061535 pmid:17951348

    CrossRefPubMed
22. 22.↵
    2. Guzmán-De-Villoria JA,
    3. Mateos-Pérez JM,
    4. Fernández-García P, et al

    . Added value of advanced over conventional magnetic resonance imaging in grading gliomas and other primary brain tumors. Cancer Imaging 2014;14:1–10 doi:10.1186/s40644-014-0035-8 pmid:25608821

    CrossRefPubMed
23. 23.↵
    2. Cuccarini V,
    3. Erbetta A,
    4. Farinotti M, et al

    . Advanced MRI may complement histological diagnosis of lower grade gliomas and help in predicting survival. J Neurooncol 2016;126:279–88 doi:10.1007/s11060-015-1960-5 pmid:26468137

    CrossRefPubMed
24. 24.↵
    2. Jain R,
    3. Gutierrez J,
    4. Narang J, et al

    . In vivo correlation of tumor blood volume and permeability with histologic and molecular angiogenic markers in gliomas. AJNR Am J Neuroradiol 2011;32:388–94 doi:10.3174/ajnr.A2280 pmid:21071537

    Abstract/FREE Full Text
25. 25.↵
    2. Tan WL,
    3. Huang WY,
    4. Yin B, et al

    . Can diffusion tensor imaging noninvasively detect IDH1 gene mutations in astrogliomas? A retrospective study of 112 cases. AJNR Am J Neuroradiol 2014;35:920–27 doi:10.3174/ajnr.A3803 pmid:24557705

    Abstract/FREE Full Text
26. 26.↵
    2. Khayal IS,
    3. Vandenberg SR,
    4. Smith KJ, et al

    . MRI apparent diffusion coefficient reflects histopathologic subtype, axonal disruption, and tumor fraction in diffuse-type grade II gliomas. Neuro Oncol 2011;13:1192–201 doi:10.1093/neuonc/nor122 pmid:21865401

    Abstract/FREE Full Text
27. 27.↵
    2. Sonoda Y,
    3. Shibahara I,
    4. Kawaguchi T, et al

    . Association between molecular alterations and tumor location and MRI characteristics in anaplastic gliomas. Brain Tumor Pathol 2015;32:99–104 doi:10.1007/s10014-014-0211-3 pmid:25537428

    CrossRefPubMed
28. 28.↵
    2. Carrillo JA,
    3. Lai A,
    4. Nghiemphu PL, et al

    . Relationship between tumor enhancement, edema, IDH1 mutational status, MGMT promoter methylation, and survival in glioblastoma. AJNR Am J Neuroradiol 2012;33:1349–55 doi:10.3174/ajnr.A2950 pmid:22322613

    Abstract/FREE Full Text
29. 29.↵
    2. Wetzel SG,
    3. Cha S,
    4. Johnson G, et al

    . Relative cerebral blood volume measurements in intracranial mass lesions: interobserver and intraobserver reproducibility study. Radiology 2002;224:797–803 doi:10.1148/radiol.2243011014 pmid:12202717

    CrossRefPubMedWeb of Science
30. 30.↵
    2. Kato Y,
    3. Jin G,
    4. Kuan CT, et al

    . A monoclonal antibody IMab-1 specifically recognizes IDH1R132H, the most common glioma-derived mutation. Biochem Biophys Res Commun 2009;390:547–51 doi:10.1016/j.bbrc.2009.10.001 pmid:19818334

    CrossRefPubMedWeb of Science
31. 31.↵
    2. Takano S,
    3. Tian W,
    4. Matsuda M, et al

    . Detection of IDH1 mutation in human gliomas: comparison of immunohistochemistry and sequencing. Brain Tumor Pathol 2011;28:115–23 doi:10.1007/s10014-011-0023-7 pmid:21344322

    CrossRefPubMedWeb of Science
32. 32.↵
    2. Higano S,
    3. Yun X,
    4. Kumabe T, et al

    . Malignant astrocytic tumors: clinical importance of apparent diffusion coefficient in prediction of grade and prognosis. Radiology 2006;241:839–46 doi:10.1148/radiol.2413051276 pmid:17032910

    CrossRefPubMedWeb of Science
33. 33.↵
    2. Murakami R,
    3. Hirai T,
    4. Sugahara T, et al

    . Grading astrocytic tumors by using apparent diffusion coefficient parameters: superiority of a one- versus two-parameter pilot method. Radiology 2009;251:838–45 doi:10.1148/radiol.2513080899 pmid:19318585

    CrossRefPubMedWeb of Science
34. 34.↵
    2. Lee EJ,
    3. Lee SK,
    4. Agid R, et al

    . Preoperative grading of presumptive low-grade astrocytomas on MR imaging: diagnostic value of minimum apparent diffusion coefficient. AJNR Am J Neuroradiol 2008;29:1872–77 doi:10.3174/ajnr.A1254 pmid:18719036

    Abstract/FREE Full Text
35. 35.↵
    2. Lee S,
    3. Choi SH,
    4. Ryoo I, et al

    . Evaluation of the microenvironmental heterogeneity in high-grade gliomas with IDH1/2 gene mutation using histogram analysis of diffusion-weighted imaging and dynamic-susceptibility contrast perfusion imaging. J Neurooncol 2015;121:141–50 doi:10.1007/s11060-014-1614-z pmid:25205290

    CrossRefPubMed
36. 36.↵
    2. Dang L,
    3. White DW,
    4. Gross S, et al

    . Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature 2009;462:739–44 doi:10.1038/nature08617 pmid:19935646

    CrossRefPubMedWeb of Science
37. 37.↵
    2. Xiong J,
    3. Tan W,
    4. Wen J, et al

    . Combination of diffusion tensor imaging and conventional MRI correlates with isocitrate dehydrogenase 1/2 mutations but not 1p/19q genotyping in oligodendroglial tumours. Eur Radiol 2016;26:1705–15 doi:10.1007/s00330-015-4025-4 pmid:26396108

    CrossRefPubMed
38. 38.↵
    2. Losman JA,
    3. Looper R,
    4. Koivunen P, et al

    . (R)-2-hydroxyglutarate is sufficient to promote leukemogenesis and its effects are reversible. Science 2013;339:1621–25 doi:10.1126/science.1231677 pmid:23393090

    Abstract/FREE Full Text
39. 39.↵
    2. Law M,
    3. Young RJ,
    4. Babb JS, et al

    . Gliomas: predicting time to progression or survival with cerebral blood volume measurements at dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging. Radiology 2008;247:490–98 doi:10.1148/radiol.2472070898 pmid:18349315

    CrossRefPubMedWeb of Science
40. 40.↵
    2. Koivunen P,
    3. Lee S,
    4. Duncan CG, et al

    . Transformation by the (R)-enantiomer of 2-hydroxyglutarate linked to EGLN activation. Nature 2012;483:484–88 doi:10.1038/nature10898 pmid:22343896

    CrossRefPubMed
41. 41.↵
    2. Mangla R,
    3. Ginat DT,
    4. Kamalian S, et al

    . Correlation between progression free survival and dynamic susceptibility contrast MRI perfusion in WHO grade III glioma subtypes. J Neurooncol 2014;116:325–31 doi:10.1007/s11060-013-1298-9 pmid:24178441

    CrossRefPubMed
42. 42.↵
    2. Zulfiqar M,
    3. Yousem DM,
    4. Lai H

    . ADC values and prognosis of malignant astrocytomas: does lower ADC predict a worse prognosis independent of grade of tumor? A meta-analysis. AJR Am J Roentgenol 2013;200:624–29 doi:10.2214/AJR.12.8679 pmid:23436853

    CrossRefPubMed